Consistently, the action of AGR2 oncoprotein was linked to inhibition of p53 phosphorylation by p38MAPK [65] and decreased p38α levels were linked to 5-FU innate and de novo resistance in colon cancer [66]. The gene discussed is TP53; the disease is colonic neoplasm.